Skip to main content

Table 1 Selected demographic and clinical characteristics of 843ADNI participants

From: Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort

 

CN

(N = 199)

SMC

(N = 85)

EMCI

(N = 239)

LMCI

(N = 207)

AD

(N = 113)

P-value

Age (years)

74.4 (5.79)

72.0(5.48)

71.4(7.30)

72.4(7.62)

75.2 (8.19)

p < 0.001

Women*

96(48%)

50(59%)

102(43%)

83(40%)

45(40%)

0.002*

Education (years)

16.2 (2.82)

16(2.79)

16.2(2.84)

16.4(2.53)

16.4(2.56)

0.764

APOE e4 allele present

47(24%)

31(36%)

99 (41%)

112(54%)

74 (65%)

p < 0.001

CDR-SOB

0.04(0.14)

0.08(0.18)

1.27(0.77)

1.65(0.94)

4.53 (1.70)

p < 0.001

Mini mental status examination

29.1(1.18)

29.0(1.2)

28.3(1.62)

27.5(1.75)

23.1 (2.05)

p < 0.001

Logical memory immediate

recall

14.42(3.00)

14.44(3.34)

11.09(2.68)

7.18(3.06)

4.15 (2.70)

p < 0.001

Logical memory delayed

recall

13.34(3.13)

13.29(3.31)

8.97(1.73)

3.94 (2.7)

1.52 (1.80)

p < 0.001

t-tau/Aβ1-42Ratio

(i.e., QT for GWAS)

0.40 (0.27)

0.37(0.24)

0.50(0.45)

0.70(0.47)

0.98 (0.49)

p < 0.001

  1. AD Alzheimer’s disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, CDR–SOB clinical dementia rating–sum of boxes, CN cognitively normal, SMC significant memory concern, EMCI early mild cognitive impairment, LMCI late mild cognitive impairment. Number (%) or mean (s.d.) was shown in each entry. P-values were assessed due to significant differences between diagnosis groups, which computed using one-way ANOVA (*except for gender using chi-square test)